Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.

Working with Ex Vivo Organ Perfusion to help manage inflammatory processes

*Not available in the US

 

The ECOS-300CY® sorbent cartridge is the first product designated and approved by under EU regulations explicitely to help removing specific cytokines and other inflammatory mediators during Ex Vivo Organ Perfusion (EVOP).
 
EVOP is a recently established technique in solid-organ transplantation in which harvested organs — such as the heart, lungs, liver, or kidneys — are perfused with oxygenated, temperature-controlled blood or perfusate outside the body.

Inflammatory mediator adsorption and organ preservation — supported by clinical evidence

Interleukin-6
Tumor necrosis factor alpha
Versatile application in a variety of organs and EVOP platforms

The ECOS-300CY® Therapy System is a CE-marked device specifically approved in the EU for the removal of cytokines and other inflammatory mediators during ex vivo organ perfusion.

ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
 
The therapy is intended for the adsorptive reduction of selected inflammatory mediators during ex vivo organ perfusion, with the goal of supporting organ preservation and functional improvement of marginal organs prior to transplantation.

Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.

The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS-300CY® sorbent cartridge represents an emerging approach under evaluation for supporting organ conditioning and preservation prior to transplantation.
 
Published pre-clinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ assessment and reconditioning.

The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.

  • ECOS-300CY is a high-flow, low-resistance adsorber designed for easy integration into the perfusate flow of an Ex Vivo Organ Perfusion (EVOP) circuit.
     
    The therapy is intended for the adsorptive reduction of selected inflammatory mediators during ex vivo organ perfusion, with the goal of supporting organ preservation and functional improvement of marginal organs prior to transplantation.

  • Viable organs for transplant are scarce and the number of patients awaiting transplant continues to grow globally, with more than 150,000 candidates awaiting transplant in Europe alone. In 2019, 41,000 patients received solid organ transplants in the EU, while 48,000 new patients were added to the transplant list and approximately 4% (or 6,000) died waiting for a transplant.

  • The combination of Ex Vivo Organ Perfusion (EVOP) with the ECOS-300CY® sorbent cartridge represents an emerging approach under evaluation for supporting organ conditioning and preservation prior to transplantation.
     
    Published pre-clinical and clinical experiences with ex vivo perfusion of solid organs demonstrate the feasibility of integrating hemoadsorption into perfusion circuits and suggest potential benefits for organ assessment and reconditioning.

  • The ECOS-300CY cartridge is available in the European Union, and also under the brand name PerSorb®, sold in conjunction with the PerLife® perfusion platform by our partner Aferetica.

Additional Information

  • Hosgood SA et al., J Transl Med. 2017; 15(1):216
  • Iskender I et al., JTCVS. 2021; 161(2):e109-e121
  • Lindstedt S et al., J Heart Lung Transplant. 2023; 42(10):1358-1362
  • Boffini M et al., Transplant Int. 2023; 36:10777
  • Niromand A et al., Front Cardiovasc Med. 2023; 10:127444

Contact us to learn more about ECOS – 300CY Therapy

Get in touch
CytoSorbents

Voices around the world

world map
Critical Care Kidney
Dr. Alessandra Lombardo
Legnano, Italy

I remember this case because it was a rhabdo like we have never seen before. And I remember CytoSorb was a very
big part of his treatment.

Critical Care
Prof. Steffen Mitzner
Rostock, Germany

What strikes you first is that you can stabilize patients in septic shock.

Critical Care
Dr. Yatin Mehta
Gurgaon, India

CytoSorb is indicated for use in conditions where elevated levels of cytokine and/or bilirubin and/or myoglobin exist.